Macroencapsulation Device with Anti-inflammatory Membrane Modification Enhances Long-Term Viability and Function of...

Area of Science:

• Biomaterials Science
• Immunology
• Endocrinology

Background:

• Type 1 diabetes (T1D) treatment via beta-cell macroencapsulation faces challenges like immune-mediated fibrosis.
• Fibrosis on macroencapsulation devices (MEDs) impairs beta-cell function and therapeutic longevity.

Purpose of the Study:

• To develop surface-modified MEDs mitigating fibrosis for improved T1D management.
• To enhance beta-cell viability, functionality, and glycemic control in a T1D model.

Main Methods:

• Surface modification of poly(tetrafluoroethylene) (PTFE) membranes using initiated chemical vapor deposition.
• Incorporation of an anti-inflammatory molecule onto the MED surface.
• Evaluation of fibrosis, beta-cell function, macrophage polarization, and glycemic control in vivo.

Main Results:

• Surface-modified MEDs significantly reduced fibrosis compared to unmodified devices.
• Improved beta-cell viability and functionality were observed with modified MEDs.
• Enhanced M2 macrophage polarization and improved glycemic control in a diabetic mouse model for 45 days.

Conclusions:

• Surface modification of MEDs is a promising strategy to overcome immune rejection in T1D therapy.
• This approach enhances therapeutic efficacy by reducing inflammation and improving beta-cell encapsulation outcomes.
• Developed MEDs show potential for improved long-term management of type 1 diabetes.